Pulmonary Embolism
Conditions
Keywords
ECOS
Brief summary
A retrospective cohort study assessed patients who underwent EKOS intervention following the failure of initial therapeutic anticoagulation for managing acute pulmonary embolism at a tertiary hospital.
Detailed description
A retrospective cohort study assessed patients who underwent EKOS intervention following the failure of initial therapeutic anticoagulation for managing acute pulmonary embolism at a tertiary hospital. Patients aged at least 18 years with a diagnosis of submassive or massive acute PE were included. Patients were excluded if they either did not receive EKOS intervention or were presented with stable PE. The primary outcome was the change in RV/LV diameter ratio from baseline to first outpatient follow-up.
Interventions
DRUGECOS
The EkoSonic Endovascular System, developed by EKOS Corporation, is a specialized CDT system that combines ultrasound technology with thrombolytic infusion to treat PE
DRUGControl group
Alteplase IV infusion
Sponsors
Beni-Suef University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients ≥ 18 years diagnosed with massive or submassive acute PE.
Exclusion criteria
1. Patients presented with stable PE 2. Patients did not receive EKOS intervention.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The change in RV/LV diameter ratio | one month | The change in RV/LV diameter ratio from baseline to first outpatient follow-up as documented on an echocardiogram. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All-cause 30-day readmission | one month | All-cause 30-day readmission |
Countries
Egypt
Outcome results
None listed